Eden Biodesign Ltd. and Selexis have expended their collaboration via a joint marketing partnership, which will provide global biopharma companies access to their services for the development of monoclonal antibodies and recombinant proteins derived from mammalian cell culture. “We are very happy to be able to formally announce our relationship with Selexis and their extremely powerful approach to the development of high-productivity cell lines, which we are able to offer to our clients,” sai...